| NCT06097260 | Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis | TERMINATED | PHASE2 | 2023-11-16 | 2025-04-04 | 2025-04-04 |
| NCT06270706 | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 | 2023-08-30 | 2025-12 | 2025-06 |
| NCT05621252 | Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) | COMPLETED | PHASE2 | 2022-07-13 | 2024-01-08 | 2023-12-27 |
| NCT04565249 | Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 | TERMINATED | PHASE2 | 2020-10-22 | 2021-08-02 | 2021-06-01 |
| NCT04480840 | Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) | COMPLETED | PHASE2 | 2020-07-27 | 2024-03-18 | 2024-02-26 |
| NCT04396756 | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis | COMPLETED | PHASE2 | 2020-03-03 | 2023-02-15 | 2023-02-01 |
| NCT04072315 | Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ | COMPLETED | PHASE2 | 2020-02-13 | 2022-07-05 | 2022-06-27 |